Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

By Oculis Holding AG | February 18, 2026, 4:05 PM

Oculis Holding AG

ZUG, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.

Attachments

Mentioned In This Article

Oculis Holding AG

Latest News

Aug-06	Oculis Reports Q2 2026 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-05	Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result OCS GuruFocus.com
Aug-03	Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses OCS +5.13% GlobeNewswire
Jul-08	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jul-02	Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference OCS GlobeNewswire
Jun-15	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jun-11	Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 OCS GlobeNewswire
Jun-10	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jun-09	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Jun-09	Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease OCS GlobeNewswire
Jun-08	Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference OCS GlobeNewswire
May-29	OCS Stock Drops Over 23% Eye Drop Trial For Diabetic Vision Loss Misses Target OCS -23.42% OCS -36.09% Stocktwits
May-29	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS -23.42% OCS -36.09% GlobeNewswire
May-29	Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema OCS -23.42% GlobeNewswire
May-28	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)